Finasteride Tablet, Film Coated
Product Images NDC 70518-3182

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 70518-3182). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Finasteride 5mg 70518 3182 01)

Finasteride 5 mg tablet packaging label shows a single film-coated tablet for oral use. The label includes the proprietary name, strength (5 mg), quantity (1 tablet), and notes 'RX ONLY'. Manufactured by Camber Pharma, with repackaging information by RemedyRepack Inc. Additional warnings and storage directions are visible on the label.*

FDA Label Image

Remedy_label (Remedy Label)

Label for Finasteride 5 mg oral film-coated tablets by RemedyRepack Inc. The label shows a quantity of 30 tablets, NDC 70518-3182-00, with manufacturer Camber Pharma, Inc. It includes storage instructions, a warning against use by women or children, and a note to see package insert for directions.*

FDA Label Image

Figure1.jpg (Figure1)

A line graph depicting mean change from baseline over four years for two groups labeled Placebo and Finasteride. Data points are shown with markers and error bars, illustrating a greater negative change over time in the Finasteride group compared to Placebo, indicating treatment effects across multiple years.*

FDA Label Image

Figure2.jpg (Figure2)

A line graph titled 'Figure 2 Percent of Patients Having Surgery for BPH, Including TURP' comparing Finasteride versus placebo over 48 months. The x-axis shows observation time in months, and the y-axis shows the percent of patients. Two lines illustrate lower surgery rates with Finasteride versus placebo. Below the graph, event counts and patient numbers for each group are listed.*

FDA Label Image

Figure3.jpg (Figure3)

A line graph showing the mean percent change from baseline over four years for two groups: placebo and finasteride. The x-axis represents time from baseline to year 4, and the y-axis shows mean percent change with a range from -20 to 20. The graph compares the progression of results for placebo versus finasteride, with sample sizes for each time point listed below the axis.*

FDA Label Image

Figure4.jpg (Figure4)

A line graph depicting the percent of participants with an event over 5.5 years from randomization, comparing four groups: Placebo, Finasteride, Doxazosin, and Combination. Each group is represented by a distinct line with markers indicating progression over time.*

FDA Label Image

Structure.jpg (Structure)

Chemical structure of Finasteride, showing its molecular framework with rings and attached functional groups, including nitrogen and oxygen atoms.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.